A carregar...
Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL) is approved for treatment of non–small-cell lung cancer. Numerous reports of ERL-associated toxicities are consistent with immune-mediated toxicity, including drug-induced hepatitis, interstitial lung disease, Stevens-Joh...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Pharmacology and Experimental Therapeutics
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3202369/ https://ncbi.nlm.nih.gov/pubmed/20382753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.109.030361 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|